CD274 and renal cell carcinoma: The phase III JAVELIN Renal 101 trial, in which 442 patients with advanced RCC were included in the avelumab–axitinib group and 444 in sunitinib monotherapy group, showed that the mPFS was 13.8 months with avelumab–axitinib versus 7.0 months with sunitinib in PD-L1 positive patients, and was 13.3 months versus 8.0 months in overall population, but the OS was immature [60].